US stock futures dip as Nvidia earnings spark little cheer
Investing.com - Cantor Fitzgerald has reiterated its Overweight rating and $45.00 price target on Sanara MedTech (NASDAQ:SMTI), a healthcare company with a market capitalization of $257 million, following the company’s announcement of a new pilot program. According to InvestingPro data, the stock is currently trading near its Fair Value, with strong revenue growth of ~35% in the last twelve months.
Sanara MedTech launched its Tissue Health Plus (THP) pilot program on Monday, representing the company’s value-based care strategy targeting non-surgical wound care.
The pilot program has been deployed across six states and utilizes THP’s Co-Pilot software to standardize care planning for patients.
The software is designed to streamline documentation and support reimbursement compliance through EMR (Electronic Medical (TASE:BLWV) Record) integration.
Cantor Fitzgerald maintained its positive outlook on Sanara MedTech as the company continues to expand its value-based care portfolio.
In other recent news, Sanara MedTech Inc. reported a 26% year-over-year revenue growth for the first quarter of 2025, achieving $23.4 million in revenue. Despite this increase, the company recorded a net loss of $3.5 million, or $0.41 per share, which fell short of analyst expectations. The revenue growth was primarily driven by strong sales in the soft tissue repair segment, with notable demand for the CellerateRX Surgical Activated Collagen. H.C. Wainwright responded to the financial results by raising its price target for Sanara MedTech to $53, maintaining a Buy rating, while Cantor Fitzgerald reaffirmed its Overweight rating with a $45 price target.
Additionally, Sanara MedTech announced the launch of a wound care provider pilot program through its subsidiary, Tissue Health Plus, LLC. This initiative aims to gather real-world data on the use of its technology platform, with plans to engage with payers for a similar pilot later in the year. The company is also seeking financial partners to support its Tissue Health Plus strategy. Sanara MedTech’s products are now available in over 4,000 hospitals and ambulatory surgery centers, marking an expansion in its market reach. These developments reflect the company’s strategic efforts to enhance its presence in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.